Evidence base and patients' perspective - World Journal of ...

More documents

Recommendations

Info

A Methylation (%) B Methylation (%) C Methylation (%) D Methylation (%) 80 60 40 20 0 100 90 80 70 60 50 40 100 80 60 40 20 100 90 80 70 60 50 40 30 Sall3-1 1 2 3 4 5,6 7 Sall3-1 1 2 3 4 5,6 7 Sall3-1 1 2 3 4 5,6 7 Sall3-1 1 2 3 4 5,6 7 10,11,12 10,11,12 10,11,12 10,11,12 WJG|www.wjgnet.com 15,16 15,16 15,16 15,16 17 17 17 17 18 18 18 18 19 19 20 21,22,23 24,25,26 CpG units (Huh7) 19 20 20 21,22,23 21,22,23 24,25,26 CpG units (HepG2) 24,25,26 CpG units (Bel7402) 19 20 21,22,23 24,25,26 CpG units (SK-HEP1) Yang XX et al . Aberrant methylation downregulate sall3 in HCC 27,28 27,28 27,28 27,28 31 31 31 31 Sall3-2 5 6 7 9 Sall3-2 5 6 7 9 Sall3-2 5 6 7 9 Sall3-2 5 6 7 9 10,11 10,11 10,11 10,11 12 12 12 12 13,14,15 13,14,15 13,14,15 13,14,15 20,21,22 20,21,22 20,21,22 20,21,22 Control 0.1 mmol 0.5 mmol 2.5 mmol Control 0.1 mmol 0.5 mmol 2.5 mmol Control 0.1 mmol 0.5 mmol 2.5 mmol Control 0.1 mmol 0.5 mmol 2.5 mmol 2723 June 7, 2012|Volume 18|Issue 21|
E Methylation (%) F Methylation (%) 100 80 60 40 20 100 80 60 40 20 0 Sall3-1 1 2 3 4 5,6 7 Sall3-1 1 2 3 4 5,6 7 tion levels in human HCC tissues are due to promoter CpG island hypermethylation, six human HCC cell lines (Huh7, HepG2, SK-HEP1, SMMC7721, Bel7402 and QGY7703) were exposed to 0, 0.1, 0.5 or 2.5 mmol 5-aza- CdR, an inhibitor of DNMTs, for 72 h. As expected, after treatment with 0.1, 0.5 or 2.5 mmol 5-aza-CdR, promoter CpG island methylation levels showed dose-dependent downregulation in all six cell lines (Figure 4). sall3 mRNA levels also showed dose-dependent upregulation 10,11,12 10,11,12 WJG|www.wjgnet.com 15,16 15,16 17 17 18 19 20 21,22,23 24,25,26 27,28 CpG units (SMMC7721) 18 19 20 21,22,23 24,25,26 27,28 CpG units (QGY7703) 31 31 Sall3-2 5 6 7 9 Sall3-2 5 6 7 9 10,11 10,11 in Huh7, HepG2, SK-HEP1 and SMMC7721 cells, while it was irregularly upregulated in Bel7402 and QGY7703 cells (Figure 5). These data indicated that sall3 promoter CpG island hypermethylation is likely responsible for the decrease in sall3 mRNA transcription level. DISCUSSION 12 12 13,14,15 13,14,15 20,21,22 20,21,22 Control 0.1 mmol 0.5 mmol 2.5 mmol Control 0.1 mmol 0.5 mmol 2.5 mmol Figure 4 Quantitative methylation analysis on each CpG unit of sall3 CpG island in HCC cells after 5-Aza-CdR treatment or control (A-F). Relative expression Yang XX et al . Aberrant methylation downregulate sall3 in HCC 6 5 4 3 2 1 0 0 Hep G2 Huh7 Bel7402 SK-HEP1 SMMC7721 QGY7703 Figure 5 Relative sall3 expression in six hepatocellular carcinoma cells after 5-AZA-CdR treatment. Error bars, SD from triplicates. 50 40 30 20 10 Control 0.1 mmol 0.5 mmol 2.5 mmol HCC is one of the most common gastrointestinal ma- 2724 June 7, 2012|Volume 18|Issue 21|
Page 1 and 2:
World Journal of Gastroenterology W
Page 3 and 4:
Phillip S Oates, Perth Ross C Smith
Page 5 and 6:
Deepak N Amarapurkar, Mumbai Abhiji
Page 7 and 8:
Trine Olsen, Tromsø Eyvind J Pauls
Page 9 and 10:
Conor P Delaney, Cleveland Sharon D
Page 11 and 12:
S Contents EDITORIAL FIELD OF VISIO
Page 13:
Contents ACKNOWLEDGMENTS APPENDIX A
Page 19:
Cereda S et al . Adjuvant treatment
Page 22 and 23:
DM, Sterling RK, Shiffman M, Topaz
Page 25 and 26:
Selinger CP et al . Pregnancy relat
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 35 and 36:
Ilan Y. Bacterial translocation in
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43:
Ettreiki C et al . Iron prevents co
Page 46 and 47:
A Macroscopir damage scores (AU) 7.
Page 48 and 49:
A Total flora 12.5 B Log copy numbe
Page 51 and 52:
Ettreiki C et al . Iron prevents co
Page 53:
Online Submissions: http://www.wjgn
Page 57 and 58:
A Fold changes over untreated cells
Page 59 and 60:
A Migration Invasion B Migration In
Page 61 and 62:
A miR-95 B Li WG et al �� Glarg
Page 64:
Key words: Colorectal cancer; Niger
Page 67 and 68:
A HT29 cells 100 C SW116 cells 40 P
Page 69 and 70:
A B Ecadherin Vimentin GAPDH Zhou H
Page 71 and 72:
Zhou HM et al �� Nigericin and
Page 73 and 74:
Terzin V et al . Serum IgG4 in auto
Page 75 and 76:
Terzin V et al . Serum IgG4 in auto
Page 77 and 78:
Online Submissions: http://www.wjgn
Page 79 and 80:
Min YW et al . Sub-centimeter-sized
Page 81 and 82:
Page 83 and 84:
Page 85:
Park CH et al . Family history and
Page 91: Online Submissions: http://www.wjgn
Page 96 and 97: genetic association study. BMC Canc
Page 98: ed ghrelin levels. World J Gastroen
Page 101 and 102: A Serum acylated ghrelin (pg/mL) B
Page 103 and 104: Yang YJ et al . H. pylori eradicati
Page 105 and 106: Online Submissions: http://www.wjgn
Page 107 and 108: Chen JG et al . Colorectal cancer s
Page 109 and 110: Chen JG et al . Colorectal cancer s
Page 111: Chen JG et al . Colorectal cancer s
Page 117 and 118: Qiao CX et al . Quality of life wit
Page 120: primary liver cancer and one of the
Page 123 and 124: A A 490 Li YH et al . GABRQ in HCC
Page 125 and 126: Li YH et al . GABRQ in HCC prostate
Page 129 and 130: Table 1 The main characteristics of
Page 131 and 132: Shen Y et al . PTEN and cetuximab e
Page 133 and 134: Shen Y et al . PTEN and cetuximab e
Page 135 and 136: Yang XX et al . Aberrant methylatio
Page 137: Relative expression 10 8 6 4 2 0 1.
Page 141 and 142: Yang XX et al . Aberrant methylatio
Page 143 and 144: Di Nardo G et al . Octreotide in pe
Page 147 and 148: A B Aniwan S et al . Infliximab for
Page 149 and 150: Aniwan S et al . Infliximab for CD
Page 151 and 152: Nishizawa T et al . Dual therapy fo
Page 153 and 154: Nishizawa T et al . Dual therapy fo
Page 157 and 158: Instructions to authors ISSN and EI
Page 159 and 160: Instructions to authors AIM (no mor
Page 161 and 162: Instructions to authors Guidelines
show all

Evidence base and patients' perspective - World Journal of ...

Create successful ePaper yourself

Delete template?

Save as template?